AMYLYX PHARMACEUTICALS INC (AMLX) — insider trading
Health Care · NASDAQ
AMYLYX PHARMACEUTICALS INC (AMLX) has 17 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 1 open-market sale among the most recent 17 (latest 2026-06-04).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | FONTEYNE PAUL R. | Director | Grant / award / vesting (derivative) | 24,372 | $0.00 | $0 | Form 4 |
| 2026-06-04 | MILNE GEORGE M JR | Director | Grant / award / vesting (derivative) | 24,372 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Quimi Daphne | Director | Grant / award / vesting (derivative) | 24,372 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Firestone Karen | Director | Grant / award / vesting (derivative) | 24,372 | $0.00 | $0 | Form 4 |
| 2026-06-04 | Zeiher Bernhardt G | Director | Grant / award / vesting (derivative) | 24,372 | $0.00 | $0 | Form 4 |
| 2026-05-21 | Firestone Karen | Director | Open-market purchase | 3,800 | $13.51 | $51.3K | Form 4 |
| 2026-03-05 | Bedrosian Camille L | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 143,985 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Bedrosian Camille L | Officer (Chief Medical Officer) | Grant / award / vesting | 95,990 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Klee Justin B. | Director, Officer (Co-Chief Executive Officer) | Grant / award / vesting (derivative) | 373,295 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Klee Justin B. | Director, Officer (Co-Chief Executive Officer) | Grant / award / vesting | 248,865 | $0.00 | $0 | Form 4 |
| 2026-03-05 | FRATES JAMES M | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 143,985 | $0.00 | $0 | Form 4 |
| 2026-03-05 | FRATES JAMES M | Officer (Chief Financial Officer) | Grant / award / vesting | 95,990 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Mazzariello Gina | Officer (Chief Legal Officer) | Grant / award / vesting (derivative) | 111,990 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Mazzariello Gina | Officer (Chief Legal Officer) | Grant / award / vesting | 74,660 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Cohen Joshua B | Director, Officer (Co-Chief Executive Officer) | Grant / award / vesting (derivative) | 373,295 | $0.00 | $0 | Form 4 |
| 2026-03-05 | Cohen Joshua B | Director, Officer (Co-Chief Executive Officer) | Grant / award / vesting | 248,865 | $0.00 | $0 | Form 4 |
| 2026-03-02 | Klee Justin B. | Director, Officer (Co-Chief Executive Officer) | Open-market sale | 29,282 | $14.47 | $423.8K | Form 4 |
Ask the chat about AMLX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AMYLYX PHARMACEUTICALS INC (AMLX).
Last updated 2026-06-04 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.